Kinney Horn - 10 Dec 2021 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
CHIEF BUSINESS OFFICER
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
10 Dec 2021
Net transactions value
-$43,720
Form type
4
Filing time
14 Dec 2021, 15:25:03 UTC
Previous filing
12 Nov 2021
Next filing
11 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Options Exercise $10,838 +5,251 +214% $2.06* 7,709 10 Dec 2021 Direct F1
transaction OLMA Common Stock Sale $54,558 -5,251 -68% $10.39 2,458 10 Dec 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OLMA Stock Option (Right to Buy) Options Exercise $0 -5,251 -3.2% $0.000000 157,540 10 Dec 2021 Common Stock 5,251 $2.06 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 668 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021.
F2 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F3 The weighted average sale price for the transaction reported was $10.39, and the range of prices were between $10.18 and $11.11. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.